Cargando…

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

Mostrar otras versiones (1)

BACKGROUND: Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gualberto, A, Hixon, M L, Karp, D D, Li, D, Green, S, Dolled-Filhart, M, Paz-Ares, L G, Novello, S, Blakely, J, Langer, C J, Pollak, M N
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039819/ https://www.ncbi.nlm.nih.gov/pubmed/21102589 http://dx.doi.org/10.1038/sj.bjc.6605972

Ejemplares similares

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2012)

Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
por: Gualberto, A, et al.
Publicado: (2011)

Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC
por: Cao, Hongxin, et al.
Publicado: (2016)

IGF-IR: a new prognostic biomarker for human glioblastoma
por: Maris, C, et al.
Publicado: (2015)

Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
por: Shimokawa, H, et al.
Publicado: (2011)

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
por: Jonker, D J, et al.
Publicado: (2014)

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009)

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel
por: Uzoh, C C, et al.
Publicado: (2011)

Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells
por: Mancini, M, et al.
Publicado: (2014)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer
por: Hsu, K-F, et al.
Publicado: (2015)

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
por: Weickhardt, A J, et al.
Publicado: (2015)

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma
por: Jacobson, B A, et al.
Publicado: (2009)

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
por: Vlahovic, G, et al.
Publicado: (2006)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
por: Codony-Servat, Jordi, et al.
Publicado: (2017)

NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines
por: Yang, Y, et al.
Publicado: (2006)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
por: Storozhuk, Y, et al.
Publicado: (2013)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity
por: Hemmerle, T, et al.
Publicado: (2013)

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015)

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
por: Marmorino, Federica, et al.
Publicado: (2017)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas
por: Slotta-Huspenina, J, et al.
Publicado: (2013)

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
por: Chang, J, et al.
Publicado: (2012)

The retinoid anticancer signal: mechanisms of target gene regulation
por: Liu, T, et al.
Publicado: (2005)

p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013)

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes
por: Murtas, D, et al.
Publicado: (2013)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
por: Qi, Lishuang, et al.
Publicado: (2016)

‘1-8 interferon inducible gene family’: putative colon carcinoma-associated antigens
por: Tirosh, B, et al.
Publicado: (2007)

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
por: Descamps, G, et al.
Publicado: (2012)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling
por: Fetoni, A R, et al.
Publicado: (2015)

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
por: Agarwal, S, et al.
Publicado: (2009)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bhgb2jpjr09rmmb39olc162l9b